Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycoprotein VI (GPVI) is a platelet membrane protein that functions as a key receptor for collagen and other ligands, playing a central role in platelet activation following vascular injury. It is crucial for the initiation of thrombus formation and has emerged as an important target for antithrombotic therapy due to its selective expression on platelets and megakaryocytes. Upon binding to collagen, GPVI initiates intracellular signaling cascades leading to platelet activation, aggregation, and thrombus formation. Targeting GPVI offers potential advantages over traditional dual-antiplatelet therapy by reducing thrombotic risk while minimizing bleeding complications.
Disrupts GPVI-mediated platelet activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycoprotein VI (None).